Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea flag South Korea · Delayed Price · Currency is KRW
13,050
+10 (0.08%)
Sep 12, 2025, 7:48 AM KST

KRX:007570 Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
16,40310,257-2,40919,38514,03210,880
Depreciation & Amortization
8,5979,82411,97111,76711,22712,664
Other Amortization
----14.9920.03
Loss (Gain) From Sale of Assets
-80.199.54-0.51-21.22-2.86-137.47
Asset Writedown & Restructuring Costs
-40-2.49-40.5125.51-263.191,947
Loss (Gain) From Sale of Investments
-68.9-27.43-30.5724.78-123.55
Loss (Gain) on Equity Investments
-1,127-2,08313,425-10,754-9,236-
Provision & Write-off of Bad Debts
29.58-52.33-393.8-964.921,06798.4
Other Operating Activities
2,7851,9013,6042,42716,8252,683
Change in Accounts Receivable
2,0261,098-1,0873,101-10,2613,085
Change in Inventory
-3,941-7,606-5,574-16,8305,7195,929
Change in Accounts Payable
-1,862-3,545-3,4256,5024,160-1,746
Change in Income Taxes
-----10,055
Change in Other Net Operating Assets
-9,296-4,157-1,421-8,77918,14711,883
Operating Cash Flow
13,4255,61514,6195,88351,42957,484
Operating Cash Flow Growth
59.60%-61.59%148.49%-88.56%-10.53%58.83%
Capital Expenditures
-20,736-38,200-5,883-3,946-12,371-10,174
Sale of Property, Plant & Equipment
26.97-0.52200.92-
Divestitures
-----3,637
Sale (Purchase) of Intangibles
-4,629-2,423-949.74-12.08-2,128-14,447
Investment in Securities
6,2893,365-4,60628,115-565.4-117.09
Other Investing Activities
-25.8582.53-77.65-14366.7-74.36
Investing Cash Flow
-19,076-37,175-11,51624,163-14,671-21,160
Short-Term Debt Issued
-68,71624,78935,00039,147-
Long-Term Debt Issued
-8,7006,000---
Total Debt Issued
51,38477,41630,78935,00039,147-
Short-Term Debt Repaid
--42,000-30,000-56,500-31,147-13,412
Long-Term Debt Repaid
--717.18-2,753-3,737-10,758-12,506
Total Debt Repaid
-36,734-42,717-32,753-60,237-41,905-25,918
Net Debt Issued (Repaid)
14,65034,699-1,965-25,237-2,758-25,918
Issuance of Common Stock
515.48515.48----
Repurchase of Common Stock
-1,000--2,000-3,000--
Dividends Paid
-2,881-2,974-2,992-3,942-2,350-4,902
Other Financing Activities
166.62-0.56-22183.5-31,524-141.56
Financing Cash Flow
11,45232,240-6,978-31,996-36,632-30,961
Foreign Exchange Rate Adjustments
184.56201.72115.33-164.64-82.48
Miscellaneous Cash Flow Adjustments
0-----
Net Cash Flow
5,986881.17-3,759-2,115125.495,446
Free Cash Flow
-7,311-32,5858,7361,93839,05747,310
Free Cash Flow Growth
--350.88%-95.04%-17.44%39.07%
Free Cash Flow Margin
-2.65%-12.12%3.28%0.78%16.11%13.78%
Free Cash Flow Per Share
-415.57-1813.13484.85106.902145.402598.70
Cash Interest Paid
4,0533,6343,3122,0961,9123,073
Cash Income Tax Paid
1,6331,5981,2395,1081,32015,299
Levered Free Cash Flow
-20,116-37,19010,211-1,03734,08025,857
Unlevered Free Cash Flow
-18,190-35,35812,227295.8635,24927,722
Change in Working Capital
-13,073-14,211-11,507-16,00617,76529,206
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.